Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Sevelamer Carbonate
Generic Name
Sevelamer Carbonate
Active Ingredient
Sevelamer CarbonateCategory
Other
Variants
46
References used for this content
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Sevelamer Carbonate, you must consult a qualified healthcare professional.
| 800 mg/1 | TABLET, FILM COATED | ORAL | 33342-215 |
| 800 mg/1 | TABLET, FILM COATED | ORAL | 58624-5001 |
| 2400 mg/2790mg | FOR SUSPENSION | ORAL | 64380-881 |
| 800 mg/1 | TABLET, FILM COATED | ORAL | 72162-2499 |
| 800 mg/1 | TABLET, FILM COATED | ORAL | 0615-8239 |
| 800 mg/1 | TABLET, FILM COATED | ORAL | 24979-186 |
| 800 mg/930mg | FOR SUSPENSION | ORAL | 64380-880 |
| 800 mg/1 | TABLET, FILM COATED | ORAL | 65862-921 |
| 800 mg/1 | TABLET, FILM COATED | ORAL | 71335-3021 |
+ 34 more variants
Detailed information about Sevelamer Carbonate
Sevelamer Carbonate is a non-absorbed phosphate binder used to control serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, helping to prevent bone disease and cardiovascular calcification.
The dosage of Sevelamer Carbonate is highly individualized and is based on the patient's current serum phosphorus levels. Healthcare providers typically follow a standardized starting regimen:
For patients switching from Sevelamer Hydrochloride to Sevelamer Carbonate, the dose is usually transitioned gram-for-gram. For patients switching from calcium-based binders, the dose is titrated based on phosphorus levels.
Sevelamer Carbonate is approved for use in children aged 6 years and older. The dosage is determined by Body Surface Area (BSA):
Titration in children follows the same logic as in adults, with adjustments made every 1-2 weeks until target phosphorus levels are achieved.
Since Sevelamer Carbonate is used specifically for patients with severe renal impairment (dialysis), no further dose adjustment is needed based on the degree of kidney failure. However, the dose must be constantly titrated based on the clinical response (serum phosphorus levels).
Because Sevelamer Carbonate is not absorbed or metabolized by the liver, no dosage adjustments are required for patients with hepatic impairment.
Clinical trials did not identify significant differences in safety or efficacy between patients over 65 and younger patients. Dose selection should be cautious, starting at the lower end of the dosing range, reflecting the greater frequency of decreased GI motility in this population.
To achieve maximum efficacy, Sevelamer Carbonate must be taken with meals. It works by binding the phosphorus in the food you are currently eating; taking it on an empty stomach significantly reduces its effectiveness.
If you miss a dose of Sevelamer Carbonate, skip the missed dose and take your next dose with your next meal. Do not take two doses at once to make up for a missed one. Since the drug only works when food is present in the gut, taking a dose between meals is generally not beneficial.
Because Sevelamer Carbonate is not absorbed, systemic toxicity from an overdose is unlikely. However, taking excessively large amounts may lead to severe constipation or gastrointestinal obstruction. If an overdose is suspected, or if the patient experiences severe abdominal pain or inability to have a bowel movement, contact a poison control center or seek emergency medical attention immediately.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without medical guidance, as this can lead to rapid increases in phosphorus levels.
Because Sevelamer Carbonate acts locally within the digestive tract, the most frequent side effects are gastrointestinal in nature. According to clinical trial data, more than 10% of patients may experience:
Sevelamer Carbonate is a potent medication that requires careful medical supervision. Patients must be aware that this drug is only one part of a comprehensive treatment plan for CKD-MBD, which also includes a low-phosphorus diet and potentially other medications like Vitamin D analogs or calcimimetics.
No FDA black box warnings for Sevelamer Carbonate. However, it is essential to adhere to the safety precautions regarding gastrointestinal health.
There are no drugs that are strictly contraindicated for use with Sevelamer Carbonate in the sense of causing a fatal reaction; however, the binding nature of the drug means it can render other life-saving medications completely ineffective if taken at the same time.
Sevelamer Carbonate is strictly contraindicated in the following scenarios:
Healthcare providers must perform a careful risk-benefit analysis for patients with:
Sevelamer Carbonate is classified as a drug where human data is limited. Because the drug is not absorbed systemically, it is not expected to be directly teratogenic (causing birth defects) to the fetus. However, its secondary effect of binding folic acid and fat-soluble vitamins is a major concern. Folic acid deficiency during pregnancy is a known cause of neural tube defects. If Sevelamer Carbonate is used during pregnancy, aggressive monitoring of vitamin levels and increased supplementation of folic acid are mandatory. The American College of Obstetricians and Gynecologists (ACOG) suggests that maintaining normal phosphorus levels is vital for maternal health, but the risks of nutrient depletion must be balanced.
Sevelamer Carbonate is not absorbed by the mother and therefore cannot be excreted into breast milk. It is generally considered safe for use during breastfeeding. However, the mother should continue to be monitored for vitamin deficiencies to ensure that the nutritional quality of the breast milk remains adequate for the infant.
Sevelamer Carbonate is FDA-approved for children aged 6 years and older. The primary concern in the pediatric population is the impact on growth. Chronic hyperphosphatemia and the resulting bone disease can lead to stunted growth and skeletal deformities. While Sevelamer is effective at lowering phosphorus in children, long-term studies on its impact on bone mineral density in growing children are still ongoing. It is not recommended for children under the age of 6.
Sevelamer Carbonate is a non-absorbed, high-molecular-weight, cross-linked polymer. It contains multiple primary and secondary amines, each separated by one carbon from the polymer backbone. In the physiological environment of the gut, these amines become partially protonated. The resulting positively charged polymer acts as an ion-exchange resin. It binds to the negatively charged phosphate ions (HPO4^2- and H2PO4^-) through a combination of ionic bonding and hydrogen bonding. By binding phosphate in the dietary bolus within the stomach and small intestine, Sevelamer prevents the transport of phosphate across the intestinal epithelium into the blood.
The pharmacodynamic effect of Sevelamer is purely local. The dose-response relationship is well-documented: higher doses of Sevelamer bind more phosphate, up to a saturation point. The onset of effect occurs with the very first meal taken with the medication, although it may take 1-2 weeks of consistent use to see a significant drop in serum phosphorus levels. Sevelamer also exhibits bile-acid sequestering activity, which can lower LDL cholesterol by approximately 15-30%.
| Parameter | Value |
Common questions about Sevelamer Carbonate
Sevelamer Carbonate is primarily used to control high phosphorus levels, a condition known as hyperphosphatemia, in adults and children at least 6 years old with chronic kidney disease who are on dialysis. When the kidneys fail, they can no longer remove phosphorus from the blood, which can lead to serious bone and heart problems. This medication works by binding to the phosphorus in the food you eat, allowing it to pass through your body without being absorbed. By keeping phosphorus levels in check, it helps prevent the loss of calcium from your bones and reduces the risk of dangerous calcium deposits in your heart and blood vessels. It is a critical component of managing mineral and bone disorder in renal patients.
The most common side effects of Sevelamer Carbonate are related to the digestive system because the drug stays in the gut and is not absorbed into the blood. Patients frequently report nausea, vomiting, stomach pain, gas, and bloating, especially when they first start the medication or increase their dose. Diarrhea and constipation are also very common, as the polymer can change the consistency of the stool. Many of these symptoms can be managed by ensuring the medication is taken exactly with meals and by following a kidney-friendly diet. If these side effects become severe or if you experience intense abdominal pain, you should contact your healthcare provider immediately.
While there is no direct chemical interaction between alcohol and Sevelamer Carbonate, drinking alcohol can complicate the management of your kidney disease. Many types of alcohol, particularly beer and certain mixed drinks, contain high amounts of phosphorus which can make the medication less effective. Additionally, alcohol can contribute to dehydration, which is a significant concern for dialysis patients who must manage their fluid intake strictly. Alcohol can also worsen some of the gastrointestinal side effects of Sevelamer, such as nausea or indigestion. It is best to consult with your nephrologist or renal dietitian to determine if a small amount of alcohol is safe for your specific health status.
Sevelamer Carbonate is generally considered to have low risk for direct birth defects because the drug is not absorbed into the mother's bloodstream and does not reach the fetus. However, it can cause a significant indirect risk by binding to essential vitamins like folic acid and Vitamin K in the mother's gut, preventing their absorption. Folic acid is crucial for the development of the baby's brain and spine, especially in the first trimester. If you are pregnant or planning to become pregnant, your doctor will need to monitor your vitamin levels very closely and may need to adjust your prenatal vitamin regimen. Always discuss the risks and benefits of continuing this medication during pregnancy with your healthcare team.
Sevelamer Carbonate begins binding phosphorus in your gut immediately with the very first dose taken with a meal. However, it usually takes several days to a few weeks of consistent use before a significant decrease in your blood phosphorus levels can be measured in a laboratory test. Doctors typically check your phosphorus levels every one to two weeks when you first start the drug to see how well it is working. Based on these results, they will 'titrate' or adjust your dose until your phosphorus falls within the target range. It is important to remember that the drug only works on the phosphorus in the food you are currently digesting, so consistency with every meal is key.
You should never stop taking Sevelamer Carbonate suddenly without first talking to your nephrologist. If you stop taking your phosphate binder, your blood phosphorus levels will likely rise very quickly to dangerous levels. High phosphorus can cause immediate symptoms like intense itching (pruritus) and can lead to long-term damage like brittle bones and calcification of your arteries. If you are struggling with the side effects or the cost of the medication, your doctor can often help by adjusting the dose, switching you to a different form like the powder, or finding an alternative phosphate binder that you tolerate better. Treatment for hyperphosphatemia is usually a lifelong requirement for patients on dialysis.
If you miss a dose of Sevelamer Carbonate, you should simply skip that dose and take your next scheduled dose with your next meal. Do not try to 'double up' or take two doses at once to make up for the one you missed. Because this medication works by binding to the phosphorus in the food you are eating at that moment, taking a dose on an empty stomach between meals is not effective and may only increase your risk of stomach upset. If you find yourself frequently forgetting doses, talk to your care team about strategies to help you remember, such as keeping a small pill container with you when you eat out.
Sevelamer Carbonate is not known to cause weight gain as a direct side effect. It does not contain calories and is not absorbed into the body's metabolic pathways. However, some patients may experience bloating or gas, which can cause a temporary feeling of heaviness or an increase in waist circumference. If you notice a rapid increase in weight, it is more likely related to fluid retention, which is a common and serious issue in kidney disease and dialysis. You should report any sudden weight gain to your dialysis center immediately, as it may indicate that your fluid removal during dialysis needs to be adjusted.
Sevelamer Carbonate can interact with many other medications by binding to them in the stomach, just as it binds to phosphorus. This can prevent your other medicines, such as antibiotics (like ciprofloxacin), thyroid medications, or transplant medications, from working correctly. To avoid this, you should generally take your other medications at least one hour before or three hours after your Sevelamer dose. This 'spacing' ensures that the other drugs have time to be absorbed into your system before the Sevelamer polymer can trap them. Always provide your doctor with a full list of all the medications and supplements you take to ensure there are no dangerous interactions.
Yes, Sevelamer Carbonate is available as a generic medication in both tablet and powder for oral suspension forms. Generic versions are required by the FDA to have the same active ingredient and work in the same way as the brand-name version, Renvela. Choosing the generic version can significantly reduce your out-of-pocket costs, which is important since this is often a long-term medication. If you are currently taking the brand-name version and wish to switch to the generic to save money, talk to your pharmacist or doctor to ensure your prescription is updated correctly. Most insurance plans and Medicare Part D cover the generic form of Sevelamer Carbonate.
Other drugs with the same active ingredient (Sevelamer Carbonate)
> Warning: Stop taking Sevelamer Carbonate and call your doctor immediately if you experience any of these serious symptoms.
One of the primary concerns with long-term use of Sevelamer Carbonate is its potential to bind to substances other than phosphate.
As of 2026, there are no FDA black box warnings for Sevelamer Carbonate. However, the FDA has issued safety communications regarding the risk of serious gastrointestinal adverse events, particularly in patients with pre-existing GI motility disorders.
Report any unusual symptoms to your healthcare provider. Your medical team can help manage side effects by adjusting your dose or suggesting dietary changes.
Patients taking Sevelamer Carbonate require regular laboratory testing to ensure safety and efficacy:
Sevelamer Carbonate is not known to cross the blood-brain barrier and does not typically cause drowsiness or cognitive impairment. It is generally considered safe to drive or operate machinery while taking this medication, provided you do not feel unwell due to gastrointestinal side effects.
There are no direct chemical interactions between Sevelamer Carbonate and alcohol. However, many alcoholic beverages (especially beer and certain dark spirits) are high in phosphorus. Excessive alcohol consumption can undermine the effectiveness of the medication in controlling phosphorus levels. Discuss your alcohol intake with your renal dietitian.
Do not stop taking Sevelamer Carbonate abruptly without consulting your nephrologist. Stopping the medication will likely result in a rapid rebound of serum phosphorus levels, which can increase the risk of cardiovascular events and bone pain. If the medication must be stopped due to side effects, your doctor will transition you to an alternative phosphate binder.
> Important: Discuss all your medical conditions, especially any history of bowel surgery or intestinal blockages, with your healthcare provider before starting Sevelamer Carbonate.
Sevelamer Carbonate is intended to interact with food. However, the type of food matters:
Sevelamer Carbonate does not typically interfere with the chemical assays used in laboratory testing. However, by changing the levels of phosphorus, calcium, and bicarbonate in the blood, it will naturally alter these lab results as part of its therapeutic effect.
Management Strategy: The general rule for managing interactions with Sevelamer Carbonate is the "1 and 3 rule." Take other medications at least 1 hour before or 3 hours after your Sevelamer dose. This allows the other medication to be absorbed before the Sevelamer polymer reaches that section of the gut.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter pain relievers and vitamins.
Patients who have had an allergic reaction to Sevelamer Hydrochloride (Renagel) are highly likely to be allergic to Sevelamer Carbonate (Renvela), as the active polymer (sevelamer) is identical in both formulations. There is no known cross-sensitivity with other classes of phosphate binders, such as Lanthanum Carbonate or Sucroferric Oxyhydroxide.
> Important: Your healthcare provider will evaluate your complete medical history, especially any history of 'lazy bowel' or previous abdominal surgeries, before prescribing Sevelamer Carbonate.
In clinical trials, approximately 28% of subjects were 65 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. However, elderly patients are more prone to constipation and have a higher prevalence of diverticular disease. Therefore, the risk of GI complications like bowel obstruction should be monitored more closely in this age group.
Sevelamer Carbonate is specifically designed for patients with end-stage renal disease (ESRD). While it is effective, it does not treat the underlying kidney failure. Patients with Stage 3 or 4 CKD (not yet on dialysis) may use the drug, but the FDA-approved labeling is focused on the dialysis population. No dose adjustment is needed for the degree of renal failure, as the drug's action is entirely independent of kidney function.
There is no need for dose adjustment in patients with liver disease. Since the drug is not processed by the liver, Child-Pugh scores do not affect the pharmacokinetics of Sevelamer Carbonate.
> Important: Special populations, particularly pregnant women and the elderly, require individualized medical assessment and more frequent laboratory monitoring.
|---|---|
| Bioavailability | 0% (Not absorbed) |
| Protein Binding | 0% (Systemic) |
| Half-life | N/A (Remains in GI tract) |
| Tmax | N/A |
| Metabolism | None (Not a substrate for CYP enzymes) |
| Excretion | Fecal (100% recovered as unchanged polymer) |
Sevelamer Carbonate is classified as a Phosphate Binder and specifically as a Non-Calcium, Non-Metal Polymeric Binder. It is often compared to other binders like Calcium Acetate (PhosLo), Lanthanum Carbonate (Fosrenol), and Sucroferric Oxyhydroxide (Velphoro).